Tag - Corbus Pharmaceuticals

Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations

Ziad2022-11-25T14:05:05-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today the appointment of Robert Discordia, Ph.D., as Vice President, Pharmaceutical Development & Manufacturing, and Ross Lobell as Vice President, Regulatory Affairs. Dr. Discordia will oversee all aspects of Corbus’ chemistry, manufacturing and controls (CMC) for lenabasum and future drug candidates. Mr. Lobell will lead Corbus’ Regulatory Affairs and Quality...

Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting

Ziad2022-11-25T14:05:05-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that its abstracts have been accepted for presentation at the European League Against Rheumatism ("EULAR") 2018 Annual Meeting being held June 13-16, 2018 in Amsterdam, Netherlands. Read more >>

Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference

Ziad2022-11-25T14:05:16-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present in a fireside chat at the 7th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 15th at 2:30 p.m. EST in New York, NY. Read more >>

Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint

Ziad2022-11-25T14:05:16-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration ("FDA") regarding the design of its next study of lenabasum (formerly known as anabasum), a novel, oral, pro-resolving drug, in the treatment of cystic fibrosis ("CF"). Read more >>

Corbus Readies Pivotal Phase 3 Trial of Anabasum, Possible Scleroderma Treatment

Ziad2022-11-25T14:05:17-05:00Corbus Pharmaceuticals is planning a global Phase 3 trial to assess anabasum (JBT-101) as a treatment for scleroderma. If successful, the company plans to apply to regulatory authorities, asking that anabasum be the first specifically approved treatment for scleroderma. Read more >>

Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Ziad2022-11-25T14:05:17-05:00Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,820,964 to the Company with claims covering the use of pharmaceutical compositions comprising anabasum for the treatment of multiple fibrotic diseases, including the Company's lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis as well as others. Read more >>

75% of Scleroderma Patients Show Meaningful Skin Improvement with Anabasum, Extension Study Shows

Ziad2022-11-25T14:05:29-05:00The thick skin that is a hallmark of scleroderma showed meaningful improvement in 75 percent of patients treated with Corbus Pharmaceuticals’ anabasum (JBT-101), according to initial results of an extension trial. Read more >>

Corbus Pharmaceuticals Receives Anabasum Patent for Inflammatory, Fibrotic Diseases

Ziad2022-11-25T14:05:29-05:00Corbus Pharmaceuticals recently announced that the U.S. Patent and Trademark Office has issued a patent for the use of anabasum, the company’s lead therapy candidate for the treatment of inflammatory and fibrotic diseases. Read more >>